University of Tasmania
Browse

File(s) under permanent embargo

Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?

journal contribution
posted on 2023-05-17, 18:10 authored by Nikpour, M, Stevens, W, Proudman, SM, Buchbinder, R, Prior, D, Zochling, J, Williams, T, Gabbay, E, Nandurkar, H
Pulmonary arterial hypertension (PAH) is a major cause of mortality in scleroderma and despite 'advanced' therapies confers a median survival of less than 5 years. Anticoagulation in systemic sclerosis-related PAH (SSc-PAH) is currently one of the most contentious issues in the management of patients with connective tissue disease. While some studies have shown a survival benefit with warfarin therapy in this disease, others have not. Accordingly, a state of clinical equipoise exists in relation to anticoagulation in SSc-PAH. With an over fivefold reduction in mortality demonstrated in some observational studies, the issue of anticoagulation in SSc-PAH demands resolution through a well-designed randomised controlled trial. © 2013 Royal Australasian College of Physicians.

History

Publication title

Internal Medicine Journal

Volume

43

Issue

5

Pagination

599-603

ISSN

1444-0903

Department/School

Menzies Institute for Medical Research

Publisher

Blackwell Publishing Asia

Place of publication

54 University St, P O Box 378, Carlton, Australia, Victoria, 3053

Rights statement

Copyright 2013 The Authors

Repository Status

  • Restricted

Socio-economic Objectives

Clinical health not elsewhere classified

Usage metrics

    University Of Tasmania

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC